Perfectus Biomed signs up two venture capital backers for infection treatment development

The £25 million North West Fund for Biomedical has made its 57th investment to date through the backing of Perfectus Biomed.

Cheshire-based Perfectus Biomed has raised £100,000 of new capital as it looks to expand its research team and implement a fresh marketing strategy in the UK and Europe.

The business, which is headquartered at one of two National Science and Innovation Campuses, conducts microbiological testing of biofilm-encased bacteria. The process is associated with discovering cures for non-healing wounds, failed medical implants and catheter infections.

Perfectus Biomed’s investment has been led by SPARK Impact, which manages The North West Fund for Biomedical. Half of the capital commitment has come from the regional fund, while the remainder is being provided by venture capital firm Midven.

With £100,000 now in the bank, Perfectus Biomed will be growing its research team so that it can conduct more testing and investing in capital assets to improve service and develop management systems within the business.

Samantha Webster, business and scientific director of Perfectus Biomed, comments, ‘[The investment] will support the growth and development of Perfectus Biomed, enabling us to increase employee numbers and drive our exciting expansion into new sectors.’

More on The North West Fund for Biomedical:

By backing Perfectus Biomed, SPARK Impact has now closed 57 transactions in 38 companies through its Biomedical Fund activity since a 2011 launch.

The £25 million pot is a sub-fund of The North West Fund, a £155 million fund provided by the European Investment Bank and the European Regional Development Fund to support equity funding in SMEs in the North West of England.

Penny Attridge, senior investment director at SPARK Impact, adds, ‘Perfectus Biomed has developed a novel research-based approach to microbiological and we’re pleased to support the firm in its growth plans.

‘Its work supports key medical sectors and we believe it to be a huge asset to SPARK’s biomedical portfolio.’

Hunter Ruthven

Hunter Ruthven

Hunter was the Editor for from 2012 to 2014, before moving on to Caspian Media Ltd to be Editor of Real Business.

Related Topics

Early Stage Funding